Previous issue | Volume 89 | ESPE2018 | Next issue

57th Annual ESPE

Athens, Greece
27 Sep 2018 - 29 Sep 2018

Card image cap
ESPE 2018 57th European Society for Paediatric Endocrinology Annual Meeting 27-29 September 2018 Athens, Greece

Rapid Free Communications

Growth and syndromes

Diagnosis of Silver-Russell Syndrome in Patients with Chromosome 14q32.2 Imprinted Region Disruption: Phenotypic and Molecular Analysis
aSorbonne Université, Paris, France; bAPHP, Paris, France; cMount Sinai, New York, New York, USA; dMAGIC, Warrenville, Illinois, USA
Molecular and Clinical Analyses of Two UPD(16)mat Patients Detected by Screening of 94 Silver-Russell Syndrome Patients without Known Etiology
aDepartment of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan; bDepartment of Pediatrics, University of Tokyo, Tokyo, Japan; cDepartment of Pediatrics, Faculty of Medicine, University of Yamanashi, Chuo, Japan; dDepartment of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan; eDepartment of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan; fDepartment of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Tokyo, Japan; gDepartment of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan
Characteristics, Effectiveness and Safety Data from Clinically Relevant Subgroups of Patients with Severeprimary IGF-I Deficiency (SPIGFD): Results from the European Increlex® Growth Forum Database (EU-IGFD) Registry
aChildren’s Hospital, University of Bonn, Bonn, Germany; bHôpital Universitaire Necker Enfants Malades, Paris, France; cUniversité Paris Descartes, Paris, France; dIpsen Pharma, Boulogne-Billancourt, France; eLinköping University, Linköping, Sweden
Effect of Adjusting for Tanner Stage Age on Short and Tall Stature Prevalence in US Youths
aEmory University, Atlanta, Georgia, USA; bUniversity of Minnesota, Minneapolis, Minnesota, USA
Latest Results from PATRO Children, a Multi-Centre, Non-Interventional Study of the Long-Term Safety and Efficacy of Omnitrope® in Children Requiring Growth Hormone Treatment
aDepartment of Paediatrics, Royal Alexandra Children’s Hospital, Brighton, UK; bDepartment of Paediatric Endocrinology, University of Leipzig Medical School, Leipzig, Germany; cPatient Area Endocrinology and Nephrology, Inflammation and Infection Theme, Karolinska University Hospital, Stockholm, Sweden; dDepartment of Clinical Science/Paediatrics, Umeå University, Umeå, Sweden; eDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Children’s Hospital, Ljubljana, Slovenia; fSandoz GmbH, Holzkirchen, Germany